Breaking News Instant updates and real-time market news.

DXCM

Dexcom

$57.81

2.26 (4.07%)

, SUPN

Supernus

$39.15

0.25 (0.64%)

08:19
11/29/17
11/29
08:19
11/29/17
08:19

Piper Jaffray to hold a conference

29th Annual Healthcare Conference is being held in New York on November 28-29 with webcasted company presentations to begin on November 29 at 8 am; not all company presentations may be webcasted. Webcast Link

DXCM

Dexcom

$57.81

2.26 (4.07%)

SUPN

Supernus

$39.15

0.25 (0.64%)

MDXG

MiMedx

$11.51

0.63 (5.79%)

TTPH

Tetraphase

$6.50

-0.01 (-0.15%)

OVID

Ovid Therapeutics

$10.71

-0.08 (-0.74%)

SBPH

Spring Bank Pharmaceuticals

$15.18

0.21 (1.40%)

AMGN

Amgen

$170.26

0.55 (0.32%)

GMED

Globus Medical

$37.69

0.3 (0.80%)

IDRA

Idera Pharmaceuticals

$2.17

-0.09 (-3.98%)

OFIX

Orthofix

$53.81

0.2 (0.37%)

ALPN

Alpine Immune Sciences

$10.67

0.68 (6.81%)

ABAX

Abaxis

$49.99

0.14 (0.28%)

INGN

Inogen

$126.46

1.13 (0.90%)

AZN

AstraZeneca

$33.52

-0.16 (-0.48%)

AMPH

Amphastar

$18.19

0.16 (0.89%)

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 01

    Dec

  • 01

    Dec

  • 02

    Dec

  • 07

    Dec

  • 14

    Dec

  • 18

    Jan

  • 03

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

DXCM Dexcom
$57.81

2.26 (4.07%)

10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/23/17
JEFF
10/23/17
NO CHANGE
Target $58
JEFF
Buy
Jefferies survey found all 60 currrent users sticking with Dexcom
Jefferies analyst Raj Denhoy surveyed 60 current users of Dexcom's (DXCM) G5 continuous glucose monitoring system and found that none plan to switch to Abbott's Libre. Approval for Libre with a favorable label and what seems to be an aggressive pricing strategy have turned Dexcom shares "toxic," Denhoy tells investors in a research note titled "What To Do With DXCM? Our Survey Says Stick With It". The analyst says that while competition will likely hurt Dexcom's near-term growth, the survey of current continuous glucose monitoring users and conversations with doctors suggest the company's outlook "might not be so dire." He cut his price target for the shares to $58 from $91 and keeps a Buy rating on the name.
10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.
11/21/17
PIPR
11/21/17
NO CHANGE
PIPR
Piper says selection for Lilly 'diabetes ecosystem' a clear positive for Dexcom
Piper Jaffray analyst Matt O'Brien said it was news to him that Eli Lilly (LLY) is developing a diabetes pump and smart pen as part of its "diabetes ecosystem" plans. The company's selection of Dexcom's (DXCM) CGM as part of their integrated system is a clear positive for Dexcom, while Lilly's launch of an integrated system in the U.S. market is a modest negative for Insulet (PODD) and Tandem Diabetes (TNDM) given it will create a competitive headwind starting in 2021, added O'Brien.
SUPN Supernus
$39.15

0.25 (0.64%)

10/19/17
10/19/17
INITIATION
Target $53

Buy
FBR sees 'strong' sales growth for Supernus, starts at Buy
FBR Capital analyst David Buck initiated Supernus Pharmaceuticals with a Buy rating and $53 price target. The analyst sees "strong" revenue growth exceeding 25% per year for 2017-2019, with in-line drugs Trokendi XR for epilepsy/migraine and Oxtellar for epilepsy driving growth. The 18% share correction from all-time highs presents an opportunity for establish positions, Buck tells investors in a research note.
11/07/17
RHCO
11/07/17
NO CHANGE
RHCO
Supernus should be bought on weakness, says SunTrust
11/07/17
STFL
11/07/17
UPGRADE
STFL
Buy
Supernus upgraded to Buy from Hold at Stifel
11/08/17
STFL
11/08/17
UPGRADE
Target $47
STFL
Buy
Supernus upgraded to Buy from Hold at Stifel
Stifel analyst Annabel Samimy upgraded Supernus Pharmaceuticals to Buy with a price target of $47 citing valuation. The analyst recommends buying the shares following yesterday's post-earnings weakness. Investor focus on the spike in gross-net in Q3 clouds the company's "stellar and consistent execution" and predictability in meeting expectations, Samimy tells investors in a research note after the shares fell 11%.
MDXG MiMedx
$11.51

0.63 (5.79%)

11/24/17
PIPR
11/24/17
NO CHANGE
Target $18
PIPR
Overweight
MiMedx business momentum 'remains stout,' says Piper Jaffray
After hosting investor meetings with management, Piper Jaffray analyst Matt O'Brien believes MiMedx's business momentum "remains stout." While the analyst does not model for it, he sees "a pathway" for MiMedx reaching its stated goal of $560M in 2020 revenue. He keeps an Overweight rating on the shares with an $18 price target.
11/17/17
PIPR
11/17/17
NO CHANGE
PIPR
Overweight
MiMedx growth shouldn't be hurt by new FDA guidelines, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien highlights the new FDA guidelines on amniotic tissue, which he says will require some labeling changes and more regulatory scrutiny for MiMedx. While the guidelines could be viewed negatively, they are largely neutral and shouldn't materially impact MiMedx's ability to grow revenue, O'Brien tells investors in a research note. The analyst adds that he can't find "credible evidence" to support the "negative commentary that surrounds the company." He continues to recommend purchase of the shares with an Overweight rating and $18 price target.
09/22/17
PIPR
09/22/17
NO CHANGE
Target $18
PIPR
Overweight
MiMedx shares offer 'highly attractive entry point,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien believes the recent pullback in shares in MiMedx Group brings a "highly attractive entry point." Short reports can have a dramatic impact in the short term, but generally end up immaterial, O'Brien tells investors in a research note after MiMedx hosted a business update call and addressed the recent reports. He believes the company has multiple catalysts to drive "significant" revenue growth in the coming years and drive the multiple higher as it transitions to a biopharma company. O'Brien has an Overweight rating on MiMedx with an $18 price target.
10/30/17
PIPR
10/30/17
NO CHANGE
Target $18
PIPR
Overweight
Piper Jaffray continues to recommend purchase of MiMedx
Piper Jaffray analyst Matt O'Brien sees room for multiple expansion and upside to revenue estimates at MiMedx Group. The analyst views the company's Q3 results as strong and thinks its "excellent product" will continue to drive sales results. O'Brien continues to recommend purchase of the shares with an Overweight rating and $18 price target.
TTPH Tetraphase
$6.50

-0.01 (-0.15%)

11/06/17
HCWC
11/06/17
NO CHANGE
Target $17
HCWC
Buy
Tetraphase price target raised to $17 from $15 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Tetraphase to $17 saying the six corporate milestones laid out in the Q3 earnings release "highlight several potential value-creating stock catalysts in 2018." The analyst believes the company is well positioned to achieve the milestones. He keeps a Buy rating on the shares.
10/05/17
BMOC
10/05/17
NO CHANGE
BMOC
Tetraphase price target raised to $24 from $13 at BMO Capital
BMO Capital analyst M. Ian Somaiya says Phase I data on the oral version of Tetraphase's eravacycline indicate that dose changes "and meal timing can effectively double drug exposure." The analyst says that the exposure levels of the oral treatment are now 80%-90% of the IV version. He raised his estimate of the oral version's chance of success to 33% from 25% and increased his price target on the shares to $24 from $13. He keeps an Outperform rating on the stock.
10/18/17
PIPR
10/18/17
NO CHANGE
Target $14
PIPR
Overweight
Piper a buyer of Tetraphase after meeting with key opinion leader
After hosting a client lunch with Dr. Andrew Shorr from MedStar Washington Hospital Center and Georgetown University, Piper Jaffray analyst Edward Tenthoff say he remains a buyer of Tetraphase Pharmaceuticals. The doctor highlighted the need for new agents to treat ESBL-producing gram-negative infections in the hospital setting, Tenthoff tells investors in a research note. He sees a place for front-line use of Tetraphase's eravacycline as well as a destination therapy. The analyst recommends buying Tetraphase ahead of a "busy" Q1 of 2018 and reiterates an Overweight rating on the name with a $14 price target.
10/06/17
RHCO
10/06/17
NO CHANGE
Target $19
RHCO
Buy
Tetraphase oral eravacycline data 'encouraging,' says SunTrust
SunTrust analyst Edward Nash says the Phase I data on oral eravacycline to be presented by Tetraphase at tomorrow's IDWeek 2017 session "shows strong promise". Nash notes that optimized fasting period around the oral dosing regimen leads to improved performance of the treatment, suggesting the IGNITE2 failure may have been the result of suboptimal food effect. The analyst maintains a Buy rating on the stock with a $19 price target.
OVID Ovid Therapeutics
$10.71

-0.08 (-0.74%)

05/30/17
05/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ovid Therapeutics (OVID) was initiated with a Buy at Citi and an Outperform at William Blair, JMP Securities, and Cowen. 2. Antero Midstream Partners (AM) was resumed with an Overweight at Morgan Stanley, initiated with an Outperform at Credit Suisse, and reinstated with an Overweight at Barclays. 3. Antero Midstream GP (AMGP) was initiated with an Overweight at Morgan Stanley, JPMorgan, and Barclays, an Outperform at Baird and Credit Suisse, a Market Perform at Wells Fargo, a Strong Buy at Raymond James, a Buy at Goldman Sachs, Ladenburg, and DA Davidson, as well as a Hold at Stifel. 4. Biohaven Pharmaceutical (BHVN) was initiated with an Outperform at William Blair, an Overweight at Piper Jaffray and Barclays, as well as a Buy at Needham. 5. Pieris Pharmaceuticals (PIRS) initiated with a Buy at Rodman & Renshaw. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/17
WBLR
05/30/17
INITIATION
WBLR
Outperform
Ovid Therapeutics initiated with an Outperform at William Blair
William Blair analyst Tim Lugo started Ovid Therapeutics with an Outperform rating saying the company is an "emerging player" in rare neurologic disorders.
05/30/17
JMPS
05/30/17
INITIATION
JMPS
Outperform
Ovid Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler started coverage of Ovid with a $26 price target and an Outperform rating. The analyst says that the company has "expertise" and a good track record. He notes that the company has developed a treatment, currently undergoing a Phase 2 trial ,for Angelman Syndrome, for which there are no approved treatments and no other drug in development. Butler adds that Ovid is developing a treatment for rare epileptic encephalopathies in conjunction with Takeda.
05/30/17
SBSH
05/30/17
INITIATION
Target $21
SBSH
Buy
Ovid Therapeutics initiated with a Buy at Citi
Target $21.
SBPH Spring Bank Pharmaceuticals
$15.18

0.21 (1.40%)

11/06/17
RILY
11/06/17
INITIATION
RILY
Buy
Spring Bank Pharmaceuticals initiated with a Buy at B. Riley FBR
07/19/17
CANT
07/19/17
INITIATION
Target $29
CANT
Overweight
Spring Bank Pharmaceuticals initiated with an Overweight at Cantor
Cantor initiated Spring Bank Pharmaceuticals with an Overweight and a $29 price target.
07/20/17
07/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Citi. 2. Johnson & Johnson (JNJ) reinstated with an Outperform at Credit Suisse. 3. Tile Shop (TTS) initiated with a Hold at Loop Capital. 4. Spring Bank Pharmaceuticals (SBPH) initiated with an Overweight at Cantor. 5. Discovery (DISCA) and Scripps Networks (SNI) were initiated with a Market Perform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/17
CHDN
05/24/17
NO CHANGE
Target $34
CHDN
Buy
Spring Bank price target doubled to $34 after Phase 2 HBV data at Chardan
Chardan analyst Madhu Kumar noted that Spring Bank Pharmaceuticals announced top-line results from the first low-dose monotherapy phase of its ACHIEVE trial for SB 9200 in the treatment of chronic hepatitis B virus infection. The efficacy signal for low-dose SB 9200 is a clear positive and dose-response in subsequent studies "could make a good story even better," the analyst tells investors. Kumar, who raised his SB 9200 launch probability to 25% from 15%, more than doubled his price target to $34 from $16.50 on Spring Bank shares. He keeps a Buy rating on the development stage drugmaker's shares.
AMGN Amgen
$170.26

0.55 (0.32%)

10/30/17
PIPR
10/30/17
NO CHANGE
PIPR
Overweight
Piper says Europe may be real battleground for biosimilar Soliris threat
Piper Jaffray analyst Christopher Raymond noted that Amgen (AMGN) recently gained EU authorization to conduct a 40 patient, cross-over design Phase 3 trial comparing their biosimilar eculizumab to Alexion's (ALXN) Soliris. He also found evidence of Amgen's active opposition to Alexion's IP extension efforts in Europe. Raymond said many "breathed a sigh of relief" that Soliris' U.S. position on Soliris appears safe out to 2027, but he said these new signs make it appear the real battleground may be Europe. He keeps an Overweight rating on Alexion, stating that "while noise from this challenge won't go away," he thinks the company is well equipped to run its defense.
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold at Argus on secular slowdown in sales of top drugs
As reported earlier, Argus analyst David Toung downgraded Amgen to Hold from Buy, noting a "secular" slowdown in sales of the company's top three products - Enbrel, Neulasta and Aranesp. Toung says the sales of growth prospects Prolia, Kyprolis and Repatha are not yet large enough to offset the declines in the three established drugs which face generic competition after losing patent protection. The analyst notes that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal challenges.
11/01/17
ARGS
11/01/17
DOWNGRADE
ARGS
Hold
Amgen downgraded to Hold from Buy at Argus
10/31/17
PIPR
10/31/17
NO CHANGE
Target $170
PIPR
Overweight
Piper says Amgen more credible biosimilar threat to Alexion in Europe
Piper Jaffray analyst Christopher Raymond believes Amgen's (AMGN) threat of a biosimilar alternative to Alexion Pharmaceuticals' (ALXN) Soliris may be more credible and near-term than he previously thought. The analyst highlights a Phase 3 study recently listed in the European Union's Clinical Trials Registry, which was authorized in August, as well as evidence of Amgen's active opposition to Alexion's intellectual property extension efforts in Europe. He reminds investors that two-thirds of Soliris' revenue is outside the U.S. Given this new evidence, "it would appear the real battleground may be Europe," Raymond tells investors in a research note. He keeps an Overweight rating on Alexion with a $170 price target. He views the company as well positioned to defend itself against Amgen.
GMED Globus Medical
$37.69

0.3 (0.80%)

10/10/17
NEED
10/10/17
NO CHANGE
Target $27
NEED
Strong Buy
K2M Group price target lowered to $27 from $29 at Needham
Needham analyst Mike Matson lowered his price target on K2M Group (KTWO) to $27 following the company's disappointing Q3 pre-announcement and a cut in FY17 revenue guidance. Matson maintains his Strong Buy rating to reflect the company's strong product cycle, potential to be acquired, and discount valuation. He attributes the Q3 shortfall for K2M to delays with signing new distributors because of longer due diligence process and weaker degenerative and deformity procedure growth. The analyst warns that other spine companies - including Globus Medical (GMED) and NuVasive (NUVA) - may be hampered by these constraints.
09/26/17
NEED
09/26/17
INITIATION
NEED
Hold
Globus Medical initiated with a Hold at Needham
Needham analyst Michael Matson initiated Globus Medical with a Hold citing fair valuation and high 2018 Street estimates.
09/07/17
BTIG
09/07/17
INITIATION
BTIG
Buy
Globus Medical initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman started coverage of Globus with a $37 price target and a Buy rating. The analyst says that the company has largely resolved the issues that had plagued its sales force, while its "best-in-class profitability profile has remained strong." Zimmerman says that the recent drop in the stock has created a buying opportunity, and he thinks it has multiple positive catalysts, including "rapid new product introductions, favorable 2H17 comps, improving market dynamics in spine, and the best EBITDA margins in spine."
11/10/17
BOFA
11/10/17
UPGRADE
Target $37
BOFA
Neutral
Globus Medical upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Bob Hopkins upgraded Globus Medical to Neutral and raised its price target to $37 from $23 based on positive physician feedbak on its new robotic platofrm.
IDRA Idera Pharmaceuticals
$2.17

-0.09 (-3.98%)

04/25/17
04/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sony (SNE) initiated with an Outperform at Bernstein. 2. Rockwell Collins (COL) reinstated with a Sell at Goldman Sachs. 3. Idera Pharmaceuticals (IDRA) initiated with an Outperform at Baird. 4. GasLog (GLOG) initiated with an Outperform at Credit Suisse. 5. Fitbit (FIT) initiated with a Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
HCWC
11/09/17
INITIATION
Target $4
HCWC
Buy
Idera Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Idera Pharmaceuticals with a Buy rating and $4 price target. The company's two lead products have "significant potential in the fast growing immunotherapy market," the analyst contends.
11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
PIPR
11/09/17
NO CHANGE
Target $4
PIPR
Overweight
Piper reiterates Overweight rating on Idera after IMO-2125 trial update
After Idera Pharmaceuticals reported a 5th unconfirmed RECIST response in its ongoing IMO-2125 plus Yervoy combo trial in PD-1 refractory metastatic melanoma, bringing the ORR to 50%, Piper Jaffray analyst Edward Tenthoff reiterated his Overweight rating and $4 price target on the stock, which is up 15% to $2.03 in midday trading.
OFIX Orthofix
$53.81

0.2 (0.37%)

06/20/17
BTIG
06/20/17
INITIATION
Target $52
BTIG
Buy
Orthofix initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman started Orthofix with a Buy rating and $52 price target, saying its strong gross margins and sizable EBITDA should result in strong free cash flow.
06/14/17
LTCO
06/14/17
INITIATION
Target $53.25
LTCO
Buy
Orthofix initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen started Orthofix with a Buy rating and $53.25 price target.
05/23/17
RHCO
05/23/17
INITIATION
RHCO
Buy
Orthofix initiated with a Buy at SunTrust
SuinTrust analyst Bruce Nudell started coverage of Orthofix with a $49 price target and a Buy rating. The analyst says that the company has improved its "operational efficiency" and can use M&a to accelerate its growth and boost its stock multiple. He thinks the company will generate "modest" organic growth and steady margins going forward, excluding any M&A.
ALPN Alpine Immune Sciences
$10.67

0.68 (6.81%)

07/27/17
07/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kinder Morgan (KMI) initiated with a Neutral at Mizuho. 2. Alpine Immune Sciences (ALPN) initiated with a Buy at Ladenburg. 3. Synaptics (SYNA) resumed with an Outperform at Cowen. 4. BioMarin (BMRN) and Ultragenyx (RARE) were initiated with a Market Perform at Bernstein. 5. Keane Group (FRAC) and ProPetro Holding (PUMP) were initiated with an Overweight at Capital One. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/27/17
LTCO
07/27/17
INITIATION
Target $17
LTCO
Buy
Alpine Immune Sciences initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Wangzhi Li started Alpine Immune Sciences with a Buy rating and $17 price target. The analyst believes the company's vIgD platform is "highly unique" in immunotherapy and holds broad potential and advantage to treat cancer, autoimmune and other diseases.
09/22/17
STFL
09/22/17
UPGRADE
STFL
Buy
Alpine Immune Sciences upgraded to Buy from Hold at Stifel
09/22/17
STFL
09/22/17
UPGRADE
STFL
Buy
Alpine Immune Sciences upgraded to Buy at Stifel
As previously reported, Stifel analyst Thomas Shrader set a Buy rating and $16 price target on Alpine Immune Sciences (ALPN), the "financial continuation" of Nivalis. That is up from the prior rating of Hold and $3.25 on its predecessor. He sees the company's focus on immune system modulation as a "timely and a powerful approach" to build additional specificity into current immunomodulatory drugs. Shrader adds that the company's collaboration with Kite Pharma (KITE) seems "more important than ever" after Gilead (GILD) comments that they plan to use excess R&D capacity to "keep up" in the evolving CAR-T/TCR space.
ABAX Abaxis
$49.99

0.14 (0.28%)

06/09/17
AGIS
06/09/17
INITIATION
Target $56.5
AGIS
Hold
Abaxis initiated with a Hold at Aegis
Aegis analyst Benjamin Haynor initiated Abaxis with a Hold and a $56.50 price target saying the company is potentially attractive but views it as a "show me" story.
08/01/17
AGIS
08/01/17
NO CHANGE
Target $129.5
AGIS
Buy
Heska price target raised to $129.50 from $114.50 at Aegis
Aegis analyst Benjamin Haynor said that following his survey results and Abaxis' (ABAX) report last week, he was "nearly certain" Heska (HSKA) would have a good quarter, which it did, beating consensus EPS estimates for the ninth straight quarter, he noted. The analyst, who said it is clear Heska is "taking share at a nice clip," sees upside to 2018 estimates and raised his price target on the stock to $129.50 from $114.50. Haynor keeps a Buy rating on Heska shares.
07/26/17
AGIS
07/26/17
NO CHANGE
AGIS
Survery suggests vet diagnostic revenue likely to beat consensus, says Aegis
Aegis analyst Ben Haynor says his survey of 360 vets indicates that the Q2 revenue of animal diagnostic equipment makers IDEXX (IDXX), Abaxis (ABXX), and Heska (HSKA) will probably beat expectations. The analyst found that vet visits rose 4.1% year-over-year last quarter, while pet owners are becoming more willing to spend money on diagnostic services.
08/23/17
BOFA
08/23/17
INITIATION
Target $42
BOFA
Underperform
Abaxis reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Derik De Bruin reinstated Abaxis with an Underperform and a $42 price target saying valuation reflects turnaround initiatives while risks remain.
INGN Inogen
$126.46

1.13 (0.90%)

05/10/17
NEED
05/10/17
NO CHANGE
Target $96
NEED
Strong Buy
Inogen price target raised to $96 from $83 at Needham
Needham analyst Mike Matson raised his price target for Inogen to $96 from $83 after the company beat consensus revenue, EBITDA, and EPS in Q1. The analyst continues to view guidance as conservative and expects Inogen's revenue growth to increase due to the ongoing G4 launch and easier comps as it laps the Medicare reimbursement cuts in 2H17. He reiterates a Strong Buy rating on the shares.
06/26/17
JPMS
06/26/17
NO CHANGE
Target $102
JPMS
Overweight
Inogen price target raised to $102 from $92 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Inogen to $102 after hosting management for investor meetings. The analyst believes the company's recent trends are "strong" and he views consensus expectations as "overly conservative." Inogen management believes their competitive lead has never been greater, Marcus tells investors in a research note. The analyst keeps an Overweight rating on the shares.
11/08/17
NEED
11/08/17
NO CHANGE
Target $125
NEED
Strong Buy
Inogen price target raised to $125 from $108 at Needham
Needham analyst Mike Matson raised his price target on Inogen to $125 and kept his Strong Buy rating following Q3 EPS beat and a raise in FY17 revenue outlook. Matson says he continues to view the management's guidance as conservative, forecasting revenue growth to increase in 2018 as it fully laps the Medicare reimbursement cut.
11/08/17
LEER
11/08/17
NO CHANGE
Target $120
LEER
Outperform
Inogen price target raised to $120 from $115 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Inogen to $120 from $115 after it delivered its 16th consecutive quarter of "solid" revenue/EPS beat since becoming a public company. The analyst reiterates an Outperform rating on the shares.
AZN AstraZeneca
$33.52

-0.16 (-0.48%)

11/20/17
HCWC
11/20/17
NO CHANGE
Target $158
HCWC
Buy
Tesaro approval in Europe gives advantage over Lynparza, says H.C. Wainwright
H.C. Wainwright analyst Edward White said Tesaro's (TSRO) receipt of marketing authorization for Zejula in Europe will give the drug an immediate advantage over AstraZeneca's (AZN) Lynparza and should help Zejula capture significant share. White keeps a Buy rating and $158 price target on Tesaro shares.
10/16/17
10/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) was upgraded to Overweight from Sector Weight at KeyBanc and Pacific Crest. 2. Infinera (INFN) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the risk/reward is balanced with material downward revisions to estimates likely limited. 3. AstraZeneca (AZN) upgraded to Outperform from Neutral at Credit Suisse with analyst Rebekah Harper saying that after recent pipeline success for Tagrisso and Imfinzi, she sees a marked improvement in its strategic position in pricing power and replacement power. 4. KKR (KKR) upgraded to Buy from Neutral at Goldman Sachs with analyst Alexander Blostein citing a more stable, improving mix of balance sheet investments, lower concentration in large public holdings, and increased mix towards private holdings. 5. Groupon (GRPN) upgraded to Market Perform from Underperform at Cowen with analyst Thomas Champion saying he believes the shares currently look more attractive given the company's new management and cost controls, improved North America results, and balanced expectations for the second half of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
AMPH Amphastar
$18.19

0.16 (0.89%)

03/14/17
03/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Corning (GLW) downgraded to Neutral from Buy at Goldman with analyst Doug Clark citing valuation with the stock up 33% since his upgrade back in April of 2016. The analyst keeps a $29 price target for the shares. 2. Amphastar (AMPH) downgraded to Outperform from Strong Buy at Raymond James with analyst Elliot Wilbur saying he sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product. 3. Abbott (ABT) downgraded to Market Perform from Outperform at BMO Capital. 4. GGP (GGP) downgraded to Neutral from Buy at UBS with analyst Jeremy Metz saying he does not see headwinds in the sector easing in the short term and cut his price target for GGP shares to $25 from $28. 5. Harmonic (HLIT) downgraded to Hold from Buy at Drexel Hamilton. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/17
RAJA
11/09/17
DOWNGRADE
RAJA
Market Perform
Amphastar downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Elliot WIlbur downgraded Amphastar to Market Perform after shares have hit his price target and said he sees few catalysts ahead to drive estimates upward.
03/14/17
RAJA
03/14/17
DOWNGRADE
Target $18
RAJA
Outperform
Amphastar downgraded to Outperform from Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur downgraded Amphastar Pharmaceuticals to Outperform and lowered his price target for the shares to $18 from $21. The analyst sees an increased near-term risk profile following indications from FDA that Amphastar may have to withdraw its epinephrine product.
07/21/17
WELS
07/21/17
NO CHANGE
WELS
Outperform
Amphastar 'David-vs-Goliath' win over Momenta a major victory, says Wells Fargo
Wells Fargo analyst David Maris said a jury's ruling that a Momenta (MNTA) patent was invalid and unenforceable is a very positive outcome for Amphastar (AMPH) in its "David-vs-Goliath-type" case. While he expects Momenta and partner Novartis' (NVS) Sandoz to appeal, Maris thinks this ruling puts Amphastar in a good position for any future potential settlement talks. Maris does not think investors should "count on any windfall" for Amphastar, but he does think, if approved, this could be an over $50M opportunity and keeps an Outperform rating on the stock, which is up 2% to $18.32 in afternoon trading.

TODAY'S FREE FLY STORIES

03:10
12/13/17
12/13
03:10
12/13/17
03:10
General news
FX Action: USD-CAD has settled in the mid 1.28s »

FX Action: USD-CAD has…

02:35
12/13/17
12/13
02:35
12/13/17
02:35
General news
FX Update: The dollar took a clobber on U.S. political news »

FX Update: The dollar…

SNY

Sanofi

$43.96

0.26 (0.59%)

02:25
12/13/17
12/13
02:25
12/13/17
02:25
Conference/Events
Sanofi to hold analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 18

    Jan

  • 25

    Mar

  • 02

    May

IRM

Iron Mountain

$37.80

-2.9 (-7.13%)

19:44
12/12/17
12/12
19:44
12/12/17
19:44
Syndicate
Iron Mountain 14.5M share Secondary priced at $37.00 »

JPMorgan, BofA/Merrill,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BTC

Bitcoin

, BITCOIN

Bitcoin

19:01
12/12/17
12/12
19:01
12/12/17
19:01
Hot Stocks
SEC chairman: Cryptocurrency tech may prove to be 'disruptive' »

SEC chairman Jay Clayton…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

STI

SunTrust

$65.54

0.92 (1.42%)

18:57
12/12/17
12/12
18:57
12/12/17
18:57
Upgrade
SunTrust rating change at Keefe Bruyette »

SunTrust upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

ZION

Zions Bancorp

$50.46

0.52 (1.04%)

18:55
12/12/17
12/12
18:55
12/12/17
18:55
Upgrade
Zions Bancorp rating change at Keefe Bruyette »

Zions Bancorp upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.58

0.37 (1.02%)

, CLLS

Cellectis

$24.02

-1.11 (-4.42%)

18:44
12/12/17
12/12
18:44
12/12/17
18:44
Hot Stocks
Pfizer's, Servier's UCART19 candidate shows high complete remission rate »

Servier, Pfizer (PFE) and…

PFE

Pfizer

$36.58

0.37 (1.02%)

CLLS

Cellectis

$24.02

-1.11 (-4.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

O

Realty Income

$55.74

0.32 (0.58%)

18:43
12/12/17
12/12
18:43
12/12/17
18:43
Hot Stocks
Realty Income raises monthly dividend to 21.25c per share from 21.2c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$81.77

0.57 (0.70%)

18:16
12/12/17
12/12
18:16
12/12/17
18:16
Earnings
Western Digital ups Q2 revenue view to $5.3B from $5.2B-$5.3B, consensus $5.2B »

Sees Q2 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTLF

Heartland Financial

$50.75

0.6 (1.20%)

18:03
12/12/17
12/12
18:03
12/12/17
18:03
Hot Stocks
Heartland Financial to acquire FBLB in roughly $185.6M deal »

Heartland Financial USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMBK

SmartFinancial

$21.82

0.03 (0.14%)

18:03
12/12/17
12/12
18:03
12/12/17
18:03
Hot Stocks
SmartFinancial and Tennessee Bancshares announce merger agreement »

SmartFinancial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBT

Welbilt

18:00
12/12/17
12/12
18:00
12/12/17
18:00
Initiation
Welbilt initiated at Barclays »

Welbilt initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMC

Vulcan Materials

$121.51

-1.41 (-1.15%)

18:00
12/12/17
12/12
18:00
12/12/17
18:00
Initiation
Vulcan Materials initiated at Barclays »

Vulcan Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

URI

United Rentals

$163.65

-0.17 (-0.10%)

17:59
12/12/17
12/12
17:59
12/12/17
17:59
Initiation
United Rentals initiated at Barclays »

United Rentals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEX

Terex

$46.53

-0.32 (-0.68%)

17:59
12/12/17
12/12
17:59
12/12/17
17:59
Initiation
Terex initiated at Barclays »

Terex initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$31.19

-0.32 (-1.02%)

17:59
12/12/17
12/12
17:59
12/12/17
17:59
Initiation
Summit Materials initiated at Barclays »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

MTZ

MasTec

$46.60

-0.25 (-0.53%)

17:58
12/12/17
12/12
17:58
12/12/17
17:58
Initiation
MasTec initiated at Barclays »

MasTec initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

MLM

Martin Marietta

$207.25

-1.43 (-0.69%)

17:58
12/12/17
12/12
17:58
12/12/17
17:58
Initiation
Martin Marietta initiated at Barclays »

Martin Marietta initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTW

Manitowoc

$39.30

-0.4 (-1.01%)

17:57
12/12/17
12/12
17:57
12/12/17
17:57
Initiation
Manitowoc initiated at Barclays »

Manitowoc initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$90.89

-1.4 (-1.52%)

17:56
12/12/17
12/12
17:56
12/12/17
17:56
Initiation
Lincoln Electric initiated at Barclays »

Lincoln Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$68.39

0.01 (0.01%)

17:55
12/12/17
12/12
17:55
12/12/17
17:55
Initiation
Jacobs Engineering initiated at Barclays »

Jacobs Engineering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRI

Herc Holdings

$60.94

-0.46 (-0.75%)

17:55
12/12/17
12/12
17:55
12/12/17
17:55
Initiation
Herc Holdings initiated at Barclays »

Herc Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$50.43

0.3 (0.60%)

17:54
12/12/17
12/12
17:54
12/12/17
17:54
Initiation
Fluor initiated at Barclays »

Fluor initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$151.07

-0.26 (-0.17%)

17:54
12/12/17
12/12
17:54
12/12/17
17:54
Initiation
Deere initiated at Barclays »

Deere initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.